Amgen details Phase 3 results of Otezla trial

 Clinically Meaningful Improvements in Physician-Reported Outcomes Maintained Through Week 32

Consistent Efficacy Was Observed at Week 16 in Subgroups of Patients with BSA <5% and BSA >5% in the Phase 3 ADVANCE Trial

Supplemental New Drug Application for Otezla to Treat Adults with Mild-to-Moderate Plaque Psoriasis Currently Under Review by the U.S. Food and Drug Administration

https://finance.yahoo.com/news/otezla-apremilast-significantly-improved-measures-200000032.html